Effectiveness of Darbepoetin alfa Administered Every 3 Weeks on Clinical Outcomes in Patients with Hematologic Malignancies and Chemotherapy-Induced Anemia.
Ralph V. Boccia(Center for Cancer and Blood Disorders), G. A. Otterson(The Ohio State University), Simon Tchekmedyian, Peter T. Silberstein(CHI Health Creighton University Medical Center - Bergan Mercy), Greg Rossi(Amgen (United States)), Dianne Tomita
Cited by 1
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
|European Journal of Cancer|1993|545
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425